Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth.

Anastasaki C, Dahiya S, Gutmann DH.

Oncotarget. 2017 Jul 18;8(29):47574-47585. doi: 10.18632/oncotarget.17736.

2.

Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Staedtke V, Bai RY, Blakeley JO.

Neurotherapeutics. 2017 Apr;14(2):298-306. doi: 10.1007/s13311-017-0518-y. Review.

PMID:
28349408
3.

The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Karmakar S, Reilly KM.

CNS Oncol. 2017 Jan;6(1):45-60. doi: 10.2217/cns-2016-0024. Epub 2016 Dec 21. Review.

PMID:
28001089
4.

The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.

Kennedy SP, Hastings JF, Han JZ, Croucher DR.

Front Cell Dev Biol. 2016 Aug 22;4:88. doi: 10.3389/fcell.2016.00088. eCollection 2016. Review.

5.

Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.

Ki DH, He S, Rodig S, Look AT.

Oncogene. 2017 Feb 23;36(8):1058-1068. doi: 10.1038/onc.2016.269. Epub 2016 Aug 1.

6.

CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.

Kendall JJ, Chaney KE, Patel AV, Rizvi TA, Largaespada DA, Ratner N.

Oncotarget. 2016 Aug 16;7(33):53191-53203. doi: 10.18632/oncotarget.10668.

7.

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Ratner N, Miller SJ.

Nat Rev Cancer. 2015 May;15(5):290-301. doi: 10.1038/nrc3911. Epub 2015 Apr 16. Review.

8.

Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.

Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA.

Neuro Oncol. 2015 Jan;17(1):63-9. doi: 10.1093/neuonc/nou140. Epub 2014 Jul 19.

9.

Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.

Patwardhan PP, Surriga O, Beckman MJ, de Stanchina E, Dematteo RP, Tap WD, Schwartz GK.

Clin Cancer Res. 2014 Jun 15;20(12):3146-58. doi: 10.1158/1078-0432.CCR-13-2576. Epub 2014 Apr 9.

10.

Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

Locati LD, Perrone F, Cortelazzi B, Imbimbo M, Bossi P, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L, Pilotti S.

Cancer Biol Ther. 2014 Jun 1;15(6):678-82. doi: 10.4161/cbt.28410. Epub 2014 Mar 11.

11.

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

Patel AJ, Liao CP, Chen Z, Liu C, Wang Y, Le LQ.

Cell Rep. 2014 Jan 16;6(1):81-92. doi: 10.1016/j.celrep.2013.12.001. Epub 2013 Dec 27.

12.

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.

Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G, Di Bartolomeo M, de Braud F.

Cancer Biol Ther. 2013 Dec;14(12):1098-103. doi: 10.4161/cbt.26343. Epub 2013 Sep 4.

13.

Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST.

Keng VW, Watson AL, Rahrmann EP, Li H, Tschida BR, Moriarity BS, Choi K, Rizvi TA, Collins MH, Wallace MR, Ratner N, Largaespada DA.

Sarcoma. 2012;2012:620834. doi: 10.1155/2012/620834. Epub 2012 Dec 18.

14.

Impaired Pten expression in human malignant peripheral nerve sheath tumours.

Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner VF, Kurtz A, Park SJ, Baier M, Harder A, Reuss D, von Deimling A, Heppner FL, Holtkamp N.

PLoS One. 2012;7(11):e47595. doi: 10.1371/journal.pone.0047595. Epub 2012 Nov 6.

15.

Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.

Sun D, Tainsky MA, Haddad R.

Transl Oncogenomics. 2012;5:1-7. doi: 10.4137/TOG.S8830. Epub 2012 Jan 18.

16.

Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Yang J, Ylipää A, Sun Y, Zheng H, Chen K, Nykter M, Trent J, Ratner N, Lev DC, Zhang W.

Clin Cancer Res. 2011 Dec 15;17(24):7563-73. doi: 10.1158/1078-0432.CCR-11-1707. Epub 2011 Oct 31.

17.

Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Brossier NM, Carroll SL.

Brain Res Bull. 2012 May 1;88(1):58-71. doi: 10.1016/j.brainresbull.2011.08.005. Epub 2011 Aug 10. Review.

18.

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL.

Fassunke J, Blum MC, Schildhaus HU, Zapatka M, Brors B, Künstlinger H, Büttner R, Wardelmann E, Merkelbach-Bruse S.

BMC Mol Biol. 2010 Dec 20;11:100. doi: 10.1186/1471-2199-11-100.

19.

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M.

J Pathol. 2010 Jan;220(1):58-70. doi: 10.1002/path.2633.

Supplemental Content

Support Center